Allarity Therapeutics Faces Delisting Concerns
Ticker: ALLR · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1860657
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Allarity Therapeutics is on the verge of being delisted.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on June 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on June 18, 2024. The company is incorporated in Delaware and its principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and valuation of the company's shares.
Risk Assessment
Risk Level: high — The company is facing a notice of delisting or failure to meet continued listing standards, which poses a significant risk to its stock.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- June 18, 2024 (date) — Earliest event reported
- June 21, 2024 (date) — Filing date
- 24 School Street, 2nd Floor, Boston, MA 02108 (location) — Principal executive offices
FAQ
What is the specific reason for Allarity Therapeutics' notice of delisting?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing', but does not detail the specific rule or standard not met.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 18, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the company's SEC file number?
The SEC file number is 001-41160.
What is the standard industrial classification for Allarity Therapeutics?
The standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-06-21 16:30:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
- $1 — Company's common stock close above the $1 per share minimum bid price requirement
Filing Documents
- ea0208266-8k_allarity.htm (8-K) — 35KB
- 0001213900-24-054800.txt ( ) — 207KB
- allr-20240618.xsd (EX-101.SCH) — 3KB
- allr-20240618_lab.xml (EX-101.LAB) — 33KB
- allr-20240618_pre.xml (EX-101.PRE) — 22KB
- ea0208266-8k_allarity_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: June 21, 2024 2